{"page":{"totalFilteredElements":381},"studies":[{"active":true,"description":"A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA","eudractNumber":"2022-502404-73","id":9114,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05968326","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-09-11T13:02:42+02:00","shortTitle":"GO44479","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"Geriatrisch-onkologische Behandlung und Intervention II<div><br /></div><div>DRKS Registrierungs-Nummer:&#160;00024974</div><div><br /></div><div>Praxisnahe Fortsetzung einer Screening-gest&#252;tzten geriatrisch-onkologischen Behandlung und Intervention (GOBI II) bei vulnerablen &#228;lteren Krebspatienten, die einer ambulanten systemonkologischen oder strahlentherapeutischen Behandlung bed&#252;rfen:&#160;</div><div>Eine monozentrische randomisierte Interventionsstudie.</div><div><br /></div><div>Kurzform: GOBI (Geriatrisch-onkologische Behandlung und Intervention) II</div><div><br /></div><div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b></div>","eudractNumber":null,"id":10932,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-07-01T10:44:59+02:00","shortTitle":"GOBI II","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"GPOH HD Study Registry 2.0<div>Prospective Registry for children and adolescents with classical Hodgkin Lymphoma, nodular lymphocyte-predominant Hodgkin Lymphoma and relapsed Hodgkin Lymphoma<br /><div><br /></div></div>","eudractNumber":null,"id":10077,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2024-10-07T13:12:30+02:00","shortTitle":"GPOH HD Study Registry 2.0","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>Deutsches MPN-Register und Biomaterialbank f&#252;r BCR-ABL/-negative<br /></div><div>myeloische Neoplasien</div>","eudractNumber":null,"id":8282,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"},{"id":"leu4","name":"Weitere hämatologische Neoplasien"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-04-06T11:07:27+02:00","shortTitle":"GSG-MPN-Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Deutsches MPN-Register und Biomaterialbank f&#252;r BCR-ABL1-negative myeloische Neoplasien<br />","eudractNumber":null,"id":4799,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"},{"id":"leu4","name":"Weitere hämatologische Neoplasien"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-12-19T08:47:11+01:00","shortTitle":"GSG-MPN-Register","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Die Rolle der Granulozyten in der Entstehung und Behandlung des Malignen Melanoms<br />","eudractNumber":null,"id":3952,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2017-06-08T09:39:21+02:00","shortTitle":"GranuMM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Gustabor Phase 1 &#8211; KI-basierte Erstellung eines Ern&#228;hrungsplans zum Ausgleich von Chemotherapie-bedingten Geschmacksst&#246;rungen","eudractNumber":null,"id":11060,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"gio4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"giu4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07040189","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-11-25T10:41:56+01:00","shortTitle":"Gustabor1","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A non-interventional study of melphalan flufenamide (melflufen, Pepaxti) in combination with dexamethasone in patients with relapsed and/ or refractory multiple myeloma (RRMM) according to the approved label<br /><div><br /></div><div>DRKS00033264</div>","eudractNumber":null,"id":9047,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-05-16T13:07:02+02:00","shortTitle":"HARBOUR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive Beobachtungsstudie zur Untersuchung potentieller Biomarker f&#252;r die Entwicklung eines Hepatozellul&#228;ren Karzinoms sowie dessen Therapie in Hinsicht Effektivit&#228;t, Vertr&#228;glichkeit und das therapeutische Ansprechen mit besonderem Augenmerk auf die Immuntherapie in einer &#8222;real-world&#8220; Kohorte (HCC-REAL, Substudie IMMUREAL)","eudractNumber":null,"id":7913,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-10-01T14:15:23+02:00","shortTitle":"HCC-REAL","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III \"PREVENT\" Trial of the AIO /CAOGI /ACO<div><br /></div>","eudractNumber":"2017-003832-35","id":6238,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04447352","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2020-12-16T12:01:06+01:00","shortTitle":"HIPEC/FLOT9 (PREVENT)","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]}]}